TVGN TEVOGEN BIO HOLDINGS INC

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account.

In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders register their shares directly with the Company’s transfer agent, Continental Stock Transfer & Trust.

The Company also notes that several of its largest shareholders, both internal and external, have elected to hold their shares via DRS, underscoring their confidence in this method of direct ownership.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
02/05/2025

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% ...

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on March 31, 2025, institutional ownership of Tevogen common stock increased by 60% compared to the reported amount on December 31, 2024. The largest contributors t...

August 8, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Re...

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well-capitalized, enabling it to fully execute its growth strategy. WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company) (Nasdaq: ), today announced it has received the $1 million in funding to adva...

August 7, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holder...

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions WARREN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on March 31, 2025, institutional ownership of Tevogen common stock increased by 60% compared to the reported amount on December 31, 2024. The largest contributors to this ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Buil...

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings In...

August 5, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion ...

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Te...

August 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch